Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 15, 2023 4:05pm EDT

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Mar 08, 2023 7:00am EST

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

Mar 02, 2023 7:00am EST

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Jan 30, 2023 4:01pm EST

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Jan 23, 2023 7:00am EST

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

Jan 12, 2023 7:00am EST

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

Dec 29, 2022 7:00am EST

Annual Shareholders Letter

Nov 02, 2022 4:02pm EDT

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Oct 27, 2022 7:00am EDT

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022

Oct 21, 2022 7:48am EDT

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...24
Next
Matinas BioPharma Holdings, Inc.

Science

  • LNC PLATFORM
  • MAT2203
  • MAT2501

Investors

  • COMPANY PROFILE
  • STOCK DATA
  • ANALYST COVERAGE
  • GOVERNANCE
  • PRESS RELEASES
  • EVENTS
  • PRESENTATIONS
  • SEC FILINGS

Company

  • OVERVIEW
  • OUR TEAM
  • NEWS
  • CAREERS
  • CONTACT US

Register for updates

Follow Us

LinkedIn facebook twitter
© 2023 Matinas BioPharma Holdings, Inc. All Rights Reserved.